Management of Chronic Obstructive Pulmonary Disease: A Personalized Interpretation of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) - ABCD Recommendations

Singh, Dave; Ravi, Arjun

doi:10.23866/brnrev:2016-m0014

Cited by 8 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1. COPD: Presence of dyspnea, cough, sputum production, and exposure to relevant risk factors, along with a positive Spirometric test (FEV1/FVC%< 70) [10]. 2.…”

Section: Methodsmentioning

confidence: 99%

Comorbidities in patients with chronic obstructive pulmonary disease: a comprehensive study

Ghafil,

Dananah,

Hassan

et al. 2023

JMedLife

View full text Add to dashboard Cite

In recent years, there has been an increasing interest in understanding the systemic nature of COPD and its frequently associated comorbidities. COPD is characterized by chronic lung disease involving local and systemic inflammation and non-reversible airway obstruction. The disease course is marked by recurrent exacerbations and is often accompanied by various comorbidities. This study aimed to evaluate the prevalence of comorbidities among Iraqi patients with COPD and their association with disease severity. A case-control study was conducted at Al-Sader Hospital in Annajaf from October 2019 to October 2020, involving 200 participants. The study population comprised 100 patients with COPD (COPD group) and 100 individuals without COPD serving as the control group. Patients with COPD were divided into four groups according to the disease severity. The prevalence of type 2 diabetes mellitus (T2DM), atherosclerotic cardiovascular diseases (ASCVD), hypertension, and dyslipidemia was determined in all groups. Patients with COPD had a significantly higher prevalence of T2DM, ASCVD, hypertension, and dyslipidemia, and, except for T2DM, the prevalence was significantly higher in the more severe groups. It was concluded that T2DM, ASCVD, hypertension, and dyslipidemia were commonly associated with COPD.

show abstract

“…1. COPD: Presence of dyspnea, cough, sputum production, and exposure to relevant risk factors, along with a positive Spirometric test (FEV1/FVC%< 70) [10]. 2.…”

Section: Methodsmentioning

confidence: 99%

Comorbidities in patients with chronic obstructive pulmonary disease: a comprehensive study

Ghafil,

Dananah,

Hassan

et al. 2023

JMedLife

View full text Add to dashboard Cite

show abstract

“…The frequency of groups A to D depends on the population studied. In the general population, the most prevalent group is A, whereas in patients recruited from secondary and tertiary care, it is D. The prevalence of group B is around 20% and group C is the least prevalent, but this is the one that is highly variable [31][32][33] .…”

Section: Comorbiditiesmentioning

confidence: 99%

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Revisions 2001-2017: Historical and Critical Perspective

Vogelmeier¹,

Criner²,

Martínez³

2017

BRN

View full text Add to dashboard Cite

In 2001, the first Global Initiative for Chronic Obstructive Lung Disease (GOLD) document was published with the goal to improve the diagnosis, prevention and treatment of chronic obstructive pulmonary disease (COPD). Since then, three major revisions (GOLD 2007(GOLD , 2011(GOLD and 2017 have been released. In this review, we describe the basic principles of the first document and how it has evolved over time. Initially, assessment was based exclusively on the level of airflow limitation. Nowadays, airflow limitation, respiratory symptom load and exacerbation history are taken into account. Bronchodilators have always been first-line. However, the indication for inhaled corticosteroids (ICS) has evolved over time. Non-pharmacological therapies are now considered to be of equal importance. In the latest version, interventional methods, palliative care, and end-of-life strategies have been added. The prevention and adequate treatment of exacerbations are highlighted and an expanded discussion of comorbidities has been added. (BRN Rev. 2017;3:151-65)

show abstract

Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders

Barrell¹

2022

EMJ

View full text Add to dashboard Cite

The negative impact of smoking on the lung is well documented. Cigarette smoke is the cause of 90% of cases of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. COPD is a progressive and debilitating condition with morbidity and mortality rates similar to myocardial infarction (MI) and stroke. Despite the widely recognised risks, millions of people continue to smoke, in some cases even after receiving a diagnosis of COPD and despite knowing that the habit will accelerate disease progression. While there is no doubt that smoking cessation is the most important health intervention for all cigarette smokers, it can be challenging. Nicotine addiction, social norms and culture, and the length of time it can take smokers to feel the adverse consequences of the habit all contribute to the high cessation failure rate. However, increasing clinical and epidemiological evidence indicates that for those who are unwilling or cannot stop smoking, harm reduction strategies can help reduce exposure to the harmful chemicals and carcinogens released during tobacco combustion. Electronic devices heat processed tobacco without combusting it to deliver an aerosol containing fewer toxic products or harmful and potentially harmful constituents (HPHC) than cigarette smoke. Clinical evidence to support their use is growing. In Japan, for example, a decrease in hospitalisations due to COPD exacerbation after the introduction of such heat-not-burn (HNB), or tobacco heating systems (THS), has been reported. In this article, Wolfgang Popp, Döbling Doctor’s Center, Privatklinik Döbling, Vienna, Austria, and Klara Szondy, Semmelweis University, Budapest, Hungary, discuss the impact of cigarette smoke on the lung, and how to support smoking cessation in those willing and able to quit smoking. They also explain when strategies that reduce the harmful effects of smoking may be useful, and outline the latest evidence supporting the use of HNB systems.

show abstract

Management of Chronic Obstructive Pulmonary Disease: A Personalized Interpretation of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) - ABCD Recommendations

Cited by 8 publications

References 65 publications

Comorbidities in patients with chronic obstructive pulmonary disease: a comprehensive study

Comorbidities in patients with chronic obstructive pulmonary disease: a comprehensive study

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Revisions 2001-2017: Historical and Critical Perspective

Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders

Contact Info

Product

Resources

About